Global Sickle Cell Disease Treatment Market

Sickle Cell Disease Treatment Comprehensive Study by Type (Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease), Application (Hospitals, Clinics, Others), Medication (Antimetabolites, Vaccines, Antibiotics, Analgesics, Folic Acid), Treatment Outlook (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant) Players and Region - Global Market Outlook to 2026

Sickle Cell Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The research on regenerative therapies such as gene therapy to treat sickle cell diseases is highly promising. Hence, many pharmaceutical vendors are researching these therapies. These advances in research will contribute significantly to drive the Global Sickle cell disease treatment market. Sickle cell anaemia is a disorder of the Red Blood Cells (RBC) is sickle cell anaemia which is an inherited disease. RBC’s have a short life span in this disease thus healthy cells does not receive adequate amount of oxygen to the organs. In normal conditions, the red blood cells move easily through the blood vessels and are flexible round in shape. Whereas In disease like sickle cell anemia the red blood cells become rigid and sticky and are sickle-shaped. Thus, RBC block the flow of oxygen and blood to the other parts of the body by getting stuck in the blood vessels. Mutation in the gene causes sickle cell anemia. Currently available treatments for sickle cell disease (SCD) provide a symptomatic relief and palliative care. The treatment includes blood transfusions, bone marrow transplant, and pharmacotherapy. Although bone marrow transplant is the only curative treatment, it is recommended only to a small percentage of patients. The disease has only two approved products hydroxyurea and Endari in the market.
This growth is primarily driven by High prevalence of Sickle cell disease patients in recent years, Investments being done by the Government and Regulatory bodies in R & D to find new therapeutic drugs and treatment for the disease and Increasing product pipeline for sickle cell disease..

Globally, a noticeable market trend is evident Favorable reimbursement policies attributed to the sickle cell disease . The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as AddMedica (France), Bristol-Mayers Squibb (United States), Emmaus Life Sciences, Inc. (United States), Novartis (Switzerland), Pfizer (United States), Baxter International Inc. (United States), Bluebird bio, Inc. (United States), Global Blood Therapeutics Inc. (United States), Sangamo Therapeutics, Inc. (United States) and Acceleron Pharma, Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In January 2019, FDA has granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD). and In December 2018, New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumaba once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated for the treatment of sickle cell disease (SCD and it shows a greater reductions of Vaso-occlusive crises (VOCs) in patients who were adherent to the treatment protocol.
In December 2018, Foundation for Sickle cell Disease Research (FSCDR) received first sickle cell hospital in Miami –Dade country. The sickle cell hospital is to expand on the services offered at FSCDR’s flagship center and includes wraparound services to improve the overall quality of life for an individual with sickle cell disease.

Market Drivers
  • High prevalence of Sickle cell disease patients in recent years
  • Investments being done by the Government and Regulatory bodies in R & D to find new therapeutic drugs and treatment for the disease
  • Increasing product pipeline for sickle cell disease.

Market Trend
  • Favorable reimbursement policies attributed to the sickle cell disease
  • Unavailability of drugs in rural areas in countries like India

Restraints
  • Lack of proper healthcare Infrastructure in MEA countries
  • High-cost treatment for Sickle cell disease

Opportunities
Increasing activities in R & D and accessibility to developed healthcare infrastructure.
Challenges
Lack of approved therapies and drugs for Sickle cell disease and Treatment of the disease is a complex procedure.

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Sickle Cell Disease Treatment Study Sheds Light on
— The Sickle Cell Disease Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Sickle Cell Disease Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Sickle Cell Disease Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Sickle Cell Anemia
  • Sickle Beta Thalassemia
  • Sickle Hemoglobin C Disease
By Application
  • Hospitals
  • Clinics
  • Others
By Medication
  • Antimetabolites
  • Vaccines
  • Antibiotics
  • Analgesics
  • Folic Acid

By Treatment Outlook
  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High prevalence of Sickle cell disease patients in recent years
      • 3.2.2. Investments being done by the Government and Regulatory bodies in R & D to find new therapeutic drugs and treatment for the disease
      • 3.2.3. Increasing product pipeline for sickle cell disease.
    • 3.3. Market Challenges
      • 3.3.1. Lack of approved therapies and drugs for Sickle cell disease
      • 3.3.2. Treatment of the disease is a complex procedure.
    • 3.4. Market Trends
      • 3.4.1. Favorable reimbursement policies attributed to the sickle cell disease
      • 3.4.2. Unavailability of drugs in rural areas in countries like India
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sickle Cell Disease Treatment, by Type, Application, Medication, Treatment Outlook and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Sickle Cell Disease Treatment (Value)
      • 5.2.1. Global Sickle Cell Disease Treatment by: Type (Value)
        • 5.2.1.1. Sickle Cell Anemia
        • 5.2.1.2. Sickle Beta Thalassemia
        • 5.2.1.3. Sickle Hemoglobin C Disease
      • 5.2.2. Global Sickle Cell Disease Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Sickle Cell Disease Treatment by: Medication (Value)
        • 5.2.3.1. Antimetabolites
        • 5.2.3.2. Vaccines
        • 5.2.3.3. Antibiotics
        • 5.2.3.4. Analgesics
        • 5.2.3.5. Folic Acid
      • 5.2.4. Global Sickle Cell Disease Treatment by: Treatment Outlook (Value)
        • 5.2.4.1. Blood Transfusion
        • 5.2.4.2. Pharmacotherapy
        • 5.2.4.3. Bone Marrow Transplant
      • 5.2.5. Global Sickle Cell Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Sickle Cell Disease Treatment (Price)
      • 5.3.1. Global Sickle Cell Disease Treatment by: Type (Price)
  • 6. Sickle Cell Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AddMedica (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Mayers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emmaus Life Sciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Baxter International Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bluebird bio, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Global Blood Therapeutics Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sangamo Therapeutics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Acceleron Pharma, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Sickle Cell Disease Treatment Sale, by Type, Application, Medication, Treatment Outlook and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Sickle Cell Disease Treatment (Value)
      • 7.2.1. Global Sickle Cell Disease Treatment by: Type (Value)
        • 7.2.1.1. Sickle Cell Anemia
        • 7.2.1.2. Sickle Beta Thalassemia
        • 7.2.1.3. Sickle Hemoglobin C Disease
      • 7.2.2. Global Sickle Cell Disease Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Sickle Cell Disease Treatment by: Medication (Value)
        • 7.2.3.1. Antimetabolites
        • 7.2.3.2. Vaccines
        • 7.2.3.3. Antibiotics
        • 7.2.3.4. Analgesics
        • 7.2.3.5. Folic Acid
      • 7.2.4. Global Sickle Cell Disease Treatment by: Treatment Outlook (Value)
        • 7.2.4.1. Blood Transfusion
        • 7.2.4.2. Pharmacotherapy
        • 7.2.4.3. Bone Marrow Transplant
      • 7.2.5. Global Sickle Cell Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Sickle Cell Disease Treatment (Price)
      • 7.3.1. Global Sickle Cell Disease Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sickle Cell Disease Treatment: by Type(USD Million)
  • Table 2. Sickle Cell Disease Treatment Sickle Cell Anemia , by Region USD Million (2015-2020)
  • Table 3. Sickle Cell Disease Treatment Sickle Beta Thalassemia , by Region USD Million (2015-2020)
  • Table 4. Sickle Cell Disease Treatment Sickle Hemoglobin C Disease , by Region USD Million (2015-2020)
  • Table 5. Sickle Cell Disease Treatment: by Application(USD Million)
  • Table 6. Sickle Cell Disease Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 7. Sickle Cell Disease Treatment Clinics , by Region USD Million (2015-2020)
  • Table 8. Sickle Cell Disease Treatment Others , by Region USD Million (2015-2020)
  • Table 9. Sickle Cell Disease Treatment: by Medication(USD Million)
  • Table 10. Sickle Cell Disease Treatment Antimetabolites , by Region USD Million (2015-2020)
  • Table 11. Sickle Cell Disease Treatment Vaccines , by Region USD Million (2015-2020)
  • Table 12. Sickle Cell Disease Treatment Antibiotics , by Region USD Million (2015-2020)
  • Table 13. Sickle Cell Disease Treatment Analgesics , by Region USD Million (2015-2020)
  • Table 14. Sickle Cell Disease Treatment Folic Acid , by Region USD Million (2015-2020)
  • Table 15. Sickle Cell Disease Treatment: by Treatment Outlook(USD Million)
  • Table 16. Sickle Cell Disease Treatment Blood Transfusion , by Region USD Million (2015-2020)
  • Table 17. Sickle Cell Disease Treatment Pharmacotherapy , by Region USD Million (2015-2020)
  • Table 18. Sickle Cell Disease Treatment Bone Marrow Transplant , by Region USD Million (2015-2020)
  • Table 19. South America Sickle Cell Disease Treatment, by Country USD Million (2015-2020)
  • Table 20. South America Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 21. South America Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 22. South America Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 23. South America Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 24. Brazil Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 25. Brazil Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 26. Brazil Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 27. Brazil Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 28. Argentina Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 29. Argentina Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 30. Argentina Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 31. Argentina Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 32. Rest of South America Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 35. Rest of South America Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 36. Asia Pacific Sickle Cell Disease Treatment, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 40. Asia Pacific Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 41. China Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 42. China Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 43. China Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 44. China Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 45. Japan Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 46. Japan Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 47. Japan Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 48. Japan Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 49. India Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 50. India Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 51. India Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 52. India Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 53. South Korea Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 54. South Korea Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 55. South Korea Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 56. South Korea Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 57. Taiwan Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 58. Taiwan Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 59. Taiwan Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 60. Taiwan Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 61. Australia Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 62. Australia Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 63. Australia Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 64. Australia Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 69. Europe Sickle Cell Disease Treatment, by Country USD Million (2015-2020)
  • Table 70. Europe Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 71. Europe Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 72. Europe Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 73. Europe Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 74. Germany Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 75. Germany Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 76. Germany Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 77. Germany Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 78. France Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 79. France Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 80. France Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 81. France Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 82. Italy Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 83. Italy Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 84. Italy Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 85. Italy Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 86. United Kingdom Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 87. United Kingdom Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 88. United Kingdom Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 89. United Kingdom Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 90. Netherlands Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 91. Netherlands Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 92. Netherlands Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 93. Netherlands Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 94. Rest of Europe Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 95. Rest of Europe Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 96. Rest of Europe Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 97. Rest of Europe Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 98. MEA Sickle Cell Disease Treatment, by Country USD Million (2015-2020)
  • Table 99. MEA Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 100. MEA Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 101. MEA Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 102. MEA Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 103. Middle East Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 104. Middle East Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 105. Middle East Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 106. Middle East Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 107. Africa Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 108. Africa Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 109. Africa Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 110. Africa Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 111. North America Sickle Cell Disease Treatment, by Country USD Million (2015-2020)
  • Table 112. North America Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 113. North America Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 114. North America Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 115. North America Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 116. United States Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 117. United States Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 118. United States Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 119. United States Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 120. Canada Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 121. Canada Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 122. Canada Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 123. Canada Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 124. Mexico Sickle Cell Disease Treatment, by Type USD Million (2015-2020)
  • Table 125. Mexico Sickle Cell Disease Treatment, by Application USD Million (2015-2020)
  • Table 126. Mexico Sickle Cell Disease Treatment, by Medication USD Million (2015-2020)
  • Table 127. Mexico Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2015-2020)
  • Table 128. Sickle Cell Disease Treatment: by Type(USD/Units)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Sickle Cell Disease Treatment: by Type(USD Million)
  • Table 140. Sickle Cell Disease Treatment Sickle Cell Anemia , by Region USD Million (2021-2026)
  • Table 141. Sickle Cell Disease Treatment Sickle Beta Thalassemia , by Region USD Million (2021-2026)
  • Table 142. Sickle Cell Disease Treatment Sickle Hemoglobin C Disease , by Region USD Million (2021-2026)
  • Table 143. Sickle Cell Disease Treatment: by Application(USD Million)
  • Table 144. Sickle Cell Disease Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 145. Sickle Cell Disease Treatment Clinics , by Region USD Million (2021-2026)
  • Table 146. Sickle Cell Disease Treatment Others , by Region USD Million (2021-2026)
  • Table 147. Sickle Cell Disease Treatment: by Medication(USD Million)
  • Table 148. Sickle Cell Disease Treatment Antimetabolites , by Region USD Million (2021-2026)
  • Table 149. Sickle Cell Disease Treatment Vaccines , by Region USD Million (2021-2026)
  • Table 150. Sickle Cell Disease Treatment Antibiotics , by Region USD Million (2021-2026)
  • Table 151. Sickle Cell Disease Treatment Analgesics , by Region USD Million (2021-2026)
  • Table 152. Sickle Cell Disease Treatment Folic Acid , by Region USD Million (2021-2026)
  • Table 153. Sickle Cell Disease Treatment: by Treatment Outlook(USD Million)
  • Table 154. Sickle Cell Disease Treatment Blood Transfusion , by Region USD Million (2021-2026)
  • Table 155. Sickle Cell Disease Treatment Pharmacotherapy , by Region USD Million (2021-2026)
  • Table 156. Sickle Cell Disease Treatment Bone Marrow Transplant , by Region USD Million (2021-2026)
  • Table 157. South America Sickle Cell Disease Treatment, by Country USD Million (2021-2026)
  • Table 158. South America Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 159. South America Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 160. South America Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 161. South America Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 162. Brazil Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 163. Brazil Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 164. Brazil Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 165. Brazil Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 166. Argentina Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 167. Argentina Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 168. Argentina Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 169. Argentina Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 170. Rest of South America Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 171. Rest of South America Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 172. Rest of South America Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 173. Rest of South America Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 174. Asia Pacific Sickle Cell Disease Treatment, by Country USD Million (2021-2026)
  • Table 175. Asia Pacific Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 176. Asia Pacific Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 177. Asia Pacific Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 178. Asia Pacific Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 179. China Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 180. China Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 181. China Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 182. China Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 183. Japan Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 184. Japan Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 185. Japan Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 186. Japan Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 187. India Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 188. India Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 189. India Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 190. India Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 191. South Korea Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 192. South Korea Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 193. South Korea Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 194. South Korea Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 195. Taiwan Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 196. Taiwan Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 197. Taiwan Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 198. Taiwan Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 199. Australia Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 200. Australia Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 201. Australia Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 202. Australia Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 207. Europe Sickle Cell Disease Treatment, by Country USD Million (2021-2026)
  • Table 208. Europe Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 209. Europe Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 210. Europe Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 211. Europe Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 212. Germany Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 213. Germany Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 214. Germany Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 215. Germany Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 216. France Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 217. France Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 218. France Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 219. France Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 220. Italy Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 221. Italy Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 222. Italy Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 223. Italy Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 224. United Kingdom Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 225. United Kingdom Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 226. United Kingdom Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 227. United Kingdom Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 228. Netherlands Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 229. Netherlands Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 230. Netherlands Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 231. Netherlands Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 232. Rest of Europe Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 233. Rest of Europe Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 234. Rest of Europe Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 235. Rest of Europe Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 236. MEA Sickle Cell Disease Treatment, by Country USD Million (2021-2026)
  • Table 237. MEA Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 238. MEA Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 239. MEA Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 240. MEA Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 241. Middle East Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 242. Middle East Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 243. Middle East Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 244. Middle East Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 245. Africa Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 246. Africa Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 247. Africa Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 248. Africa Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 249. North America Sickle Cell Disease Treatment, by Country USD Million (2021-2026)
  • Table 250. North America Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 251. North America Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 252. North America Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 253. North America Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 254. United States Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 255. United States Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 256. United States Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 257. United States Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 258. Canada Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 259. Canada Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 260. Canada Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 261. Canada Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 262. Mexico Sickle Cell Disease Treatment, by Type USD Million (2021-2026)
  • Table 263. Mexico Sickle Cell Disease Treatment, by Application USD Million (2021-2026)
  • Table 264. Mexico Sickle Cell Disease Treatment, by Medication USD Million (2021-2026)
  • Table 265. Mexico Sickle Cell Disease Treatment, by Treatment Outlook USD Million (2021-2026)
  • Table 266. Sickle Cell Disease Treatment: by Type(USD/Units)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sickle Cell Disease Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Sickle Cell Disease Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Sickle Cell Disease Treatment: by Medication USD Million (2015-2020)
  • Figure 7. Global Sickle Cell Disease Treatment: by Treatment Outlook USD Million (2015-2020)
  • Figure 8. South America Sickle Cell Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Sickle Cell Disease Treatment Share (%), by Country
  • Figure 10. Europe Sickle Cell Disease Treatment Share (%), by Country
  • Figure 11. MEA Sickle Cell Disease Treatment Share (%), by Country
  • Figure 12. North America Sickle Cell Disease Treatment Share (%), by Country
  • Figure 13. Global Sickle Cell Disease Treatment: by Type USD/Units (2015-2020)
  • Figure 14. Global Sickle Cell Disease Treatment share by Players 2020 (%)
  • Figure 15. Global Sickle Cell Disease Treatment share by Players (Top 3) 2020(%)
  • Figure 16. Global Sickle Cell Disease Treatment share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AddMedica (France) Revenue, Net Income and Gross profit
  • Figure 19. AddMedica (France) Revenue: by Geography 2020
  • Figure 20. Bristol-Mayers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol-Mayers Squibb (United States) Revenue: by Geography 2020
  • Figure 22. Emmaus Life Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Emmaus Life Sciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2020
  • Figure 28. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Baxter International Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Bluebird bio, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bluebird bio, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Global Blood Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Global Blood Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Sangamo Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Sangamo Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Acceleron Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Acceleron Pharma, Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Global Sickle Cell Disease Treatment: by Type USD Million (2021-2026)
  • Figure 39. Global Sickle Cell Disease Treatment: by Application USD Million (2021-2026)
  • Figure 40. Global Sickle Cell Disease Treatment: by Medication USD Million (2021-2026)
  • Figure 41. Global Sickle Cell Disease Treatment: by Treatment Outlook USD Million (2021-2026)
  • Figure 42. South America Sickle Cell Disease Treatment Share (%), by Country
  • Figure 43. Asia Pacific Sickle Cell Disease Treatment Share (%), by Country
  • Figure 44. Europe Sickle Cell Disease Treatment Share (%), by Country
  • Figure 45. MEA Sickle Cell Disease Treatment Share (%), by Country
  • Figure 46. North America Sickle Cell Disease Treatment Share (%), by Country
  • Figure 47. Global Sickle Cell Disease Treatment: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AddMedica (France)
  • Bristol-Mayers Squibb (United States)
  • Emmaus Life Sciences, Inc. (United States)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Baxter International Inc. (United States)
  • Bluebird bio, Inc. (United States)
  • Global Blood Therapeutics Inc. (United States)
  • Sangamo Therapeutics, Inc. (United States)
  • Acceleron Pharma, Inc. (United States)
Additional players considered in the study are as follows:
Arena Pharmaceuticals, Inc. (United States) , Alnylam Pharmaceuticals, Inc. (United States) , Modus Therapeutics (Sweden)
Select User Access Type

Key Highlights of Report


Dec 2021 120 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sickle Cell Disease Treatment Market Quantitative research analysis
Global Sickle Cell Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Sickle Cell Disease Treatment market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Sickle Cell Disease Treatment market are AddMedica (France), Bristol-Mayers Squibb (United States), Emmaus Life Sciences, Inc. (United States), Novartis (Switzerland), Pfizer (United States), Baxter International Inc. (United States), Bluebird bio, Inc. (United States), Global Blood Therapeutics Inc. (United States), Sangamo Therapeutics, Inc. (United States) and Acceleron Pharma, Inc. (United States), to name a few.
North America is dominating the Sickle Cell Disease Treatment Market.

Know More About Global Sickle Cell Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Exosome Diagnostics and Therapeutics Comprehensive Study by Type (Diagnostic, Therapeutic), Application (Cancer Institute, Hospital, Diagnostic Center, Others), Components (Instrument, Reagent, Softw...
$ 3750
Gonorrhea Testing Comprehensive Study by Test (Nucleic Acid Amplification (NAA), Gram Stain, Enzyme-linked immunosorbent assay (ELISA), Gonorrhea Culture, Rapid test), Sample (Blood, Lymph fluid, Uri...
$ 3450
Microwave Therapeutic Instruments Comprehensive Study by Type (Monopolar, Bipolar), Application (Arthritis, Back Pain, Fibromyalgia, Muscle Spasms, Myositis, Neuralgia, Sprains And Strains, Tenosynov...
$ 3650
Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750
Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030
$ 3500
Oligodendroglioma Treatment Comprehensive Study by Treatment Type Names (Surgery, Radiotherapy, Chemotherapy), Type of Oligodendroglioma (Pure Oligodendroglioma, Mixed Oligodendroglioma), Grade Type ...
$ 3350